13:56 , Sep 20, 2018 |  BC Extra  |  Preclinical News

RNA-modifying enzyme loops mRNA to increase oncogene translation

Boston Children's Hospital researchers showed interaction between a translation factor and RNA-modifying enzyme could enhance oncogene translation by circularizing mRNA, suggesting that disrupting the protein-protein interaction could help treat cancer. At least two companies -- Storm...
19:08 , May 18, 2018 |  BC Week In Review  |  Financial News

RNA epigenetics company Accent raises $40M series A

RNA epigenetics company Accent Therapeutics Inc. (Lexington, Mass.) debuted with a $40 million series A co-led by The Column Group and Atlas Venture, with participation from EcoR1 Capital. Accent’s preclinical assets are designed to treat cancer...
09:12 , May 18, 2018 |  BC Extra  |  Financial News

Accent targeting RNA-modifying proteins with $40M series A

RNA epigenetics company Accent Therapeutics Inc. (Lexington, Mass.) debuted with a $40 million series A co-led by The Column Group and Atlas Venture, with participation from EcoR1 Capital. Accent’s preclinical assets are designed to treat cancer...
09:09 , May 18, 2018 |  BioCentury  |  Emerging Company Profile

Accent on RNA

With its debut Friday with a $40 million series A, Accent Therapeutics Inc. became the second disclosed newco to jump into the nascent arena of RNA epigenetics. The biotech has identified enzymes it believes drive...